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Summary TGF-,B is the prototype of a large family of multifunctional regulatory proteins. The principal
sources of the peptide, platelets and bone, suggest that it plays a role in healing and remodeling processes. In
vitro, TGF-fl is chemotactic for monocytes and fibroblasts and can greatly enhance accumulation of
extracellular matrix components by fibroblasts. Its ability to stimulate the formation of granulation tissue
locally and the demonstration of specific time- and tissue-dependent expression in embryogenesis suggest that
similar mechanisms are operative in vivo. By analogy to its effects in wound healing and embryogenesis, it is
proposed that TGF-fl, secreted by tumour cells, can augment tumour growth indirectly by effects on the
stromal elements. These effects include suppression of the immune response, and enhancement of both
angiogenesis and formation of connective tissue. Many tumour cells have escaped from direct growth
inhibitory effects of TGF-# by a variety of mechanisms including inability to activate the latent form of the
peptide, loss of cellular receptors for TGF-fl, and loss of functional intracellular signal transduction pathways.
Transforming growth factor-# (TGF-f,) is the prototype of
a large family of multifunctional peptides. First purified to
homogeneity in 1983 (Assoian et al., 1983; Frolik et al.,
1983; Roberts et al., 1983), and cloned in 1985 (Derynck
et al., 1985), it is one of the newest of the set of polypeptide
growth factors which are now recognized as having central
roles in controlling cellular activities. Yet the almost
universal range of target cells for TGF-,B, the breadth of the
scope of biological activities which it controls, and its high
degree of evolutionary conservation, have resulted in
recognition of TGF-f as a principal regulator of many
physiological and pathological processes. In this brief review,
we will present data relating to a multifaceted role for
TGF-f in embryogenesis and the normal processes of
inflammation and repair, as well as in pathological diseases
such as cancer (for other reviews see Sporn et al., 1987;
Roberts et al., 1988).
Chemistry of TGF-f3J and 2
TGF-# is now known to exist principally in two homologous
forms, called TGF-#l and TGF-#2 (Cheifetz et al., 1987),
with TGF-#l usually more abundant than TGF-,B2. TGF-,BI
is a homodimeric peptide of 25,000 M, each chain of which
is encoded as a 390 amino acid precursor and subsequently
processed to a C-terminal 112 amino acid fragment (Derynck
et al., 1985). TGF-#2 is encoded as a somewhat larger
precursor of 414 amino acids, but is also processed to a 112
amino acid fragment that is 71% homologous to TGF-ll
(Marquardt et al., 1987; de Martin et al., 1987).
Conservation of each of these two peptides is very strong.
The mature TGF-#l peptide is identical in man, cow, pig,
and monkey and differs by only one amino acid in mouse;
the N-terminal 30 amino acids of mature TGF-#2 are also
identical in man, cow, and pig. In most biological systems,
TGF-f,l and 2 can act interchangeably, but distinct actions
are beginning to be found, as well (Ohta et al., 1987; Rosa et
al., 1988; see also Sporn & Roberts, 1988a).
TGF-,ll is found in highest amounts in platelets (Assoian
et al., 1983) and in bone (Seyedin et al., 1985) suggesting
that it might play a major role in tissue repair and bone
remodeling. The major proportion of the TGF-,ll released
from platelets or from cells is in a biologically inactive
'latent' form that must be activated before it can interact
with its receptor. Since acidification is the principal mode of
activation of the latent form in vitro (Lawrence et al., 1985),
TGF-,ll that has been purified from platelets by steps
involving low pH is permanently activated. Recent work by
Wakefield et al. (1987a) demonstrates that the latent
complex of TGF-#l results from association of the
remaining portion of the TGF-#l precursor with the
processed dimer. TGF-fl2 also exists in a latent form
(Conner et al., 1988; Danielpour et al., 1988); whether or not
it will also be found to be complexed with the corresponding
portion of its precursor remainder remains to be determined.
Activation of the latent forms of TGF-#1 and 2 possibly
represents the principal physiological control mechanism of
TGF-fl activity (Wakefield et al., 1987a). What the actual
physiological mechanisms of activation might be and
whether distinct mechanisms might be operative for
activation ofTGF-fll and 2 are important questions.
Family ofTGF-f peptides
Over the last two years, several proteins have been described
which clearly have evolved from the same ancestral gene as
the TGF-fls. These proteins, which are listed in Table I and
include the mammalian peptides Mullerian inhibitory
substance (MIS), the inhibins, and the activins, as well as the
putative products of the DPP-C gene in Drosophila and the
Vgl gene in Xenopus, belong to the TGF-fl family, based on
the homologous positioning of 7-9 of the cysteine residues of
TGF-f (the monomeric unit of TGF-# contains 9 cysteine
residues). Like the TGF-fs, each of these proteins is encoded
as a larger precursor and, with the exception of MIS,
subsequently processed to a C-terminal monomeric unit of
100-134 amino acids. The homology among family members
is confined to these processed, C-terminal peptides, which, in
all cases known thus far, are biologically active only in
homodimeric form (the putative products of the DPP-C and
Vgl genes have not yet been isolated).
With the exception of TGF-#l and 2, which share some
receptor cross-reactivity (Cheifetz et al., 1987; Segarini et al.,
1987), each of the family members is thought to act through
distinct membrane receptors and each has a unique function
(Table I). However, despite these differences, many of these
peptides have in common that they control aspects of
development: thus MIS controls regression of the female
anlage of the embryonic male reproductive system; the
inhibins and activins presumably play a role in sexual
maturation and sexual cycle in females; the product of the
DPP-C gene controls dorsal-ventral patterning in Drosophila,
and the product of the Vgl gene is thought to function in
induction of mesoderm from amphibiam ectoderm. As will
be discussed below, TGF-ll and 2 also play critical roles in
embryogenesis, though the exact mechanisms are not yet
understood.
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Table I Properties of members of the TGF-beta gene family
Mol wt
Peptide daltons
TGF-,BI
TGF-,B2
Inhibins
Activins
MIS
DPP-C
Vgl
25,000
25,000
32,000
Function
Multifunctional regulator of cell
growth, differentiation and function
same function as TGF-fll
Inhibit secretion of FSH by
pituitary cells
28,000 Stimulate secretion of FSH by
pituitary cells
140,000 Induces regression of Miillerian
ducts in male embryos
? Establishment of dorsal-ventral
specification in Drosophila embryos
? Functions in the induction of
mesoderm during frog development
Reference
(cloning)
Derynck et al. (1985)
de Martin et al. (1987)
Mason et al. (1985)
Ling et al. (1986)
Vale et al. (1986)
Cate et al. (1986)
Padgett et al. (1987)
Weeks & Melton (1987)
Multifunctional aspects of TGF-f3 action
One of the hallmarks of TGF-# has been the multi-
functional nature of its action (see Tables II and III).
Depending on the conditions, TGF-# can act to either
stimulate or inhibit cellular proliferation, cellular
differentiation, or cellular function (see Sporn et al., 1987).
Although it is now recognized that the actions of most
peptide growth factors are likewise multifunctional (Sporn &
Roberts, 1988b), the wide spectrum of target cells for TGF-#
makes this aspect all the more apparent. As shown in Table
II, TGF-# can either synergize with or antagonize the
actions of other growth factors such as epidermal growth
factor (EGF), platelet-derived growth factor (PDGF),
fibroblast growth factor (FGF), or tumour necrosis factor-cx
(TNF-cx). In the examples cited, the other growth factors
have a consistent mitogenic activity; TGF-fl, on the other
hand, can function as either a mitogen or as a growth
inhibitor for many cell types (Tucker et al., 1984; Roberts et
al., 1985). Thus the activity of the peptide is not an intrinsic
property of that factor, but is defined by the entire set of
conditions operant on the cell. Some of the conditions which
can alter the apparent effect of TGF-# on growth of
fibroblastic cells are outlined in Table III; these include the
type of cell, the growth conditions, the total set of growth
factors present, as well as the state of differentiation of the
cells. These additional levels of complexity serve to greatly
increase the spectrum of cellular responses to a relatively
small number of peptide growth factors.
Role of TGF-f3 in embryogenesis
As discussed earlier, one common thread linking the actions
of peptides belonging to the TGF-f family is their effects on
various aspects of embryonic development. Recent immuno-
histochemical studies of TGF-#l in the developing mouse
embryo, undertaken in our laboratory, now clearly show
that TGF-#l also plays a critical role in mammalian
embryogenesis (Heine et al., 1987). Northern blot analysis of
TGF-#l mRNA levels during mouse embryogenesis showed
that message levels were high throughout embryonic
development, in contrast to genes such as those for TGF-
alpha, fibronectin, and type I collagen, which were more
highly expressed in the early, middle, and late periods of
gestation, respectively. Earlier studies had shown that TGF-
fl-like activity could be found in extracts of mouse embryos
(Proper et al., 1982; Hill et al., 1986b), but only a limited
amount of information was available regarding the immuno-
localization of TGF-#1 in the embryo (Ellingsworth et al.,
1986).
The results of the immunohistochemical studies clearly
demonstrate that TGF-Jl is expressed in a unique pattern,
both spatially and temporally, in the developing mouse
embryo (Heine et al., 1987). Overall, TGF-fl was most highly
associated with tissues derived from mesenchyme, such as
connective tissue, cartilage, and bone. At days 13-15 of
gestation, staining was particularly conspicuous in tissues
derived from neural crest mesenchyme, such as the
developing palate, larynx, facial mesenchyme, nasal sinuses,
meninges, and teeth. In many tissues, the staining pattern
appears to correlate with specific morphogenetic and histo-
genetic events, particularly those involving cells and tissues
of mesenchymal or mesodermal origin; for example, intense
staining of TGF-,B is seen during formation of the digits
from limb buds, the formation of the palate, and formation
of the heart valves. In addition, TGF-# staining was found
in tissues in which critical mesenchymal-epithelial inter-
actions occur (Hay, 1981), such as in the formation of the
hair follicles and teeth, the submandibular gland, and the
intestine. As an example, in the snout, diffuse TGF-,ll
staining is seen at early stages before formation of the hair
follicles of the vibrissae; at day 15, staining is concentrated
in the mesenchyme surrounding the follicles, and at day 18,
when the follicles have matured, no more staining is seen.
Although these studies were focused on the relatively later
stages of embryogenesis where organogenesis was occurring,
Table II Bifunctional effects of TGF-# on the action of other growth factors
Growth
factor Synergistic effects References Antagonistic effects References
EGF growth of NRK or smooth Anzano et al. (1983) growth of A549 or Roberts et al. (1985)
muscle cells in soft agar Assoian et al. (1986) myc-FR-3T3 cells in soft agar
PDGF growth of NRK or myc-FR3T3 Assoian et al. (1984) growth of rat embryo Anzano et al. (1986)
cells in soft agar Roberts et al. (1985) fibroblasts
FGF induction of mesoderm from Kimelman & Kirschner growth of endothelial cells Baird & Durkin (1987)
amphibian ectoderm (1987)
TNF-a growth of osteoblasts Centrella et al. (1987) generation of cytotoxic Ranges et al. (1987)
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Table III Multifunctionality of TGF-,B in fibroblasts
TGF-,B can either stimulate or inhibit cellular proliferation of the
fibroblastic cells depending on:
1. the particular cell type
stimulates growth of osteoblasts (Robey et al., 1987); inhibits
growth of fibroblasts (Roberts et al., 1985).
2. the growth conditions
stimulates growth of NRK cells in soft agar; inhibits growth of
NRK cells in monolayer culture (Roberts et al., 1985).
3. the total set ofgrowth factors acting on the cell
stimulates growth of myc-FR3T3 cells in the presence of PDGF;
inhibits their growth in the presence of EGF (Roberts et al.,
1985).
4. the state ofdifferentiation of the cell
stimulates growth of early human embryo fibroblasts; inhibits
growth of later stage embryo fibroblasts (Hill et al., 1986a).
recent observations on the effects of TGF-/ on amphibian
embryogenesis suggest that it also has effects on one of the
earliest stages of embryogenesis, namely establishment of the
germ layers. Thus, TGF-# synergizes with FGF to exert a
potent inductive effect on the formation of mesoderm from
ectoderm in amphibian embryos (Kimelman & Kirschner,
1987). In other studies, it has been shown that TGF-fl2, and
not TGF-#1, can act alone to induce mesoderm, suggesting
that these two homologues may have unique actions in
embryogenesis (Rosa et al., 1988). Since the bulk of the
vertebrate organism is composed of mesodermal cells and
tissues, these studies suggest that TFG-fl participates in some
fundamental way in the basic architecture and organization
of almost the entire developing embryo.
The mechanisms whereby TGF-# controls differentiation
and morphogenesis in the embryo are not yet understood.
However, it is likely that they involve some of the same
effects of TGF-,B on cell movements, cellular activation, and
synthesis of matrix proteins which are important in physio-
logical repair processes and pathological disease processes
mediated by TGF-P in the adult, and which will be discussed
below.
Role of TGF-f3 in granulation tissue and tumour stroma
It has often been suggested that there is a common basis
between wound healing and carcinogenesis (Haddow, 1972;
Dvorak, 1986). The common basis lies in the similarity of
the composition of the granulation tissue of a healing wound
and the tumour stroma. Each is composed of three elements:
inflammatory cells, newly formed blood vessels, and
connective tissue (Dvorak, 1986). The major difference
between the processes of wound healing and carcinogenesis
is the orchestrated, finite nature of the healing response
compared to the continuous growth of the tumour. We
propose that the major mechanistic link between these
processes is the action of growth factors (Sporn & Roberts,
1986; Roberts et al., 1988). In a wound, platelet lysis results
in release of a single bolus of growth factors which initiates
a cascade of events involving other cell types such as
macrophages, lymphocytes, endothelial cells, and fibroblasts;
platelets are the major sources of PDGF and TGF-,B and
contain lesser quantities of EGF-like and TGF-like peptides
as well. In contrast, in carcinogenesis, tumour cells
continuously release some of the same growth factors found
in platelets, including PDGF (Bowen-Pope et al., 1984) and
TGF-fl (Anzano et al., 1985; Derynck et al., 1987). The
major difference is that the continuous release of growth
factors by tumour cells perpetuates the response, in effect
constantly reinitiating the healing cascade.
Experiments addressing the in vivo activity of TGF-,B1 in
the newborn mouse showed that it could stimulate formation
of a localized fibrous nodule with all of the characteristics of
granulation tissue; that is, it contained inflammatory cells
and showed new blood vessel formation and elaboration of
connective tissue (Roberts et al., 1985). These experiments
showed that TGF-fl, alone, was sufficient to initiate the
entire cascade of events resulting in the formation of granu-
lation tissue and suggested that secretion of TGF-j by
tumour cells could have similar effects on stromal elements.
Attempts to understand either of these processes must begin
with an analysis of the participating cell types and their
abilities to both secrete and respond to various growth
factors. Studies in the past two years have greatly increased
our understanding of the effects of TGF-# on tumour cells,
as well as on stromal elements including inflammatory cells,
endothelial cells and fibroblasts. These effects on the
different participating cell types will be discussed, as they
relate to both wound healing and carcinogenesis. Exogenous
TGF-#1 and 2 are interchangeable in each of the systems
discussed; however, the particular type of TGF-,B secreted by
the cells has not yet been determined.
Effects of TGF-f on monocytes are multiple; at very low
concentrations (1 pgml-1), TGF-# is chemotactic for
monocytes, while at considerably higher concentrations (1-
lOngml-1), TGF-f can activate monocytes to express and
secrete other growth factors such as interleukin-1 (Wahl et
al., 1987). Not only do monocytes respond to TGF-/3, but
activation of monocytes results in secretion by the cells of
TGF-f (Assoian et al., 1987); this can serve to sustain the
action of the peptide in the cascade of events in wound
healing or to increase local concentrations of TGF-# in
carcinogenesis.
Effects of TGF-# on lymphocytes are uniformly
inhibitory. TGF-f inhibits the proliferation of both T-
(Kehrl et al., 1986b) and B-lymphocytes (Kehrl et al., 1986a),
and blocks antibody secretion by B cells. It also is inhibitory
to other lymphocyte subtypes including natural killer cells
(Rook et al., 1986) and lymphokine-activated killer cells
(Mule et al., 1988). As found with monocytes, activation of
T-lymphocytes results in secretion of TGF-fl. Since it has
been found that the secretion of TGF-,B is delayed in time
from the onset of activation, it has been suggested that
TGF-fl may play a role in return of the activated
lymphocyte to its resting state. Consistent with these in vitro
suppressive effects of TGF-# on lymphocytes, the recent
identification of TGF-f2 as the principal immunosuppressive
agent in patients with glioblastoma suggests that these effects
occur in vivo as well and furthermore that secretion by
tumour cells, such as glioblastoma cells, of immuno-
suppressive factors like TGF-# can decrease immune sur-
veillance of the tumour and thereby indirectly favour tumour
growth (Wrann et al., 1987).
Effects of TGF-# on endothelial cells are complicated in
that most of the in vitro effects are growth inhibitory (see for
example Baird & Durkin, 1986), yet the peptide is angiogenic
in vivo (Roberts et al., 1986). In an in vitro assay system in
whic endothelial cells are grown in a collagen matrix, it has
been shown that TGF-# can induce tube formation, in the
absence of cellular proliferation (Madri et al., 1988). The
higher order tissue architecture of capillary formation
requires more than simple proliferation of cells, and it
cannot be ruled out that TGF-# will be found to affect this
organizational process and possibly also stimulate indirectly
the proliferation of the cells via growth factors secreted by
macrophages which it can attract and activate.
Effects of TGF-,B on fibroblasts are multifaceted and
constitiute, perhaps, the most unique and important aspects
of TGF-f biology. As found for monocytes, TGF-# is
chemotactic for fibroblasts, although at slightly higher
concentrations (1Opgml-1; Postlethwaite et al., 1987).
Again, higher concentrations of TGF-f8 activate fibroblasts,
in this case to synthesize and accumulate matrix proteins. It
is now clear that TGF-f, acts at three different levels to
control accumulation of matrix proteins (for reviews see
Sporn et al., 1987; Roberts et al., 1988).
The first mechanism whereby TGF-fl acts to increase
accumulation of matrix proteins such as collagen andTRANSFORMING GROWTH FACTOR-f 597
fibronectin is by directly increasing their synthesis (Ignotz &
Massague, 1986; Roberts et al., 1986; Ignotz et al., 1987).
Recent studies using constructs of the promotor of mouse
alpha 2(I)collagen have shown that treatment of cells with
either TGF-fll or 2, but not with PDGF or EGF, results in
transcriptional activation of the promotor (Rossi et al.,
1988). Deletion analysis has identified a short stretch of
nucleotides known to mediate binding of a transcription
factor, nuclear factor 1 (NF-1), which are required for the
inductive effects of TGF-# on collagen gene expression.
Whether NF-I will also mediate the effects of TGF-,B on
expression of other genes such as protease inhibitors is a
problem of intense interest.
The second mechanism whereby TGF-# acts to control
accumulation of matrix proteins is by control of their
proteolytic degradation. This occurs both by decreased
synthesis and secretion of proteases and by increased
synthesis and secretion ofprotease inhibitors. As an example,
treatment of fibroblasts with TGF-1I results in decreased
secretion of the serine protease plasminogen activator as well
as increased secretion of plasminogen activator inhibitor
(Laiho et al., 1986). Levels of the thiol protease, major
excreted protein (Chiang & Nilsen-Hamilton, 1986), and of
the metalloproteases, stromelysin and collagenase (Matrisian
et al., 1986; Edwards et al., 1987) have also been found to
decrease, while increases have been found in the levels of
tissue inhibitor of metalloproteineases (Edwards et al., 1987).
Once the promoters for these genes are isolated, it will be
exciting to test whether regulation of their expression by
TGF-fl, like that of the genes for the matrix proteins,
themselves, might also be mediated by a NF-1 binding site.
Finally, recent experiments by Ignotz and Massague (1987)
have shown that there is yet a third mechanism whereby
TGF-f controls aspects of matrix protein biology; treatment
of cells with TGF-,B has been shown to result in increased
a
synthesis of the receptor for fibronectin, and possibly for
other integrins as well. These three mechanisms, which
assure both increased synthesis and increased response to
matrix proteins, are probably central to the increases in
connective tissue proteins associated with both healing and
carcinogenesis, as well as to many of the effects of TGF-f
on cell growth and differentiation both in vitro and in
embryogenesis.
Immunohistochemical analyses of TGF-f,l in a severely
dysplastic villoglandular polyp from human colon (Figure
la) and in a hepatic granuloma (Figure lb) induced in rats
by systemic injection of Group A streptococcal cell walls
(Allen et al., 1985) show a similar pattern of stromal
staining. In each case, the staining is associated with extra-
cellular matrix and is in a region where fibroblasts and/or
inflammatory cells predominate. The antibody used for these
studies (Ellingworth et al., 1986) has been found to stain
principally extracellular rather than intracellular TGF-f,1,
suggesting that the staining pattern reflects areas of deposi-
tion of TGF-31, rather than sites of synthesis (unpublished).
The staining pattern is consistent with secretion of TGF-fl by
activated inflammatory cells (Assoian et al., 1987; Wahl et
al., 1987) and premalignant colon adenomas (Wigley et al.,
1986) and colon cancer cell lines (Coffey et al., 1987). The
similar staining patterns of these two sections, one of
granulation tissue and one of a premalignant dysplastic
lesion, are consistent with the common nature of these two
tissues as discussed above.
Loss ofnegative autocrine growth control by tumour cells
In terms of a model for TGF-f action in carcinogenesis, it is
known that most tumour cells express TGF-,B mRNA
(Derynck et al., 1987) and that many secrete TGF-fl, and we
have proposed that such growth factor secretion might result
b
rigure Ilmmunonistocnemicai staining ot paraiiin sections with IgG to the N-terminal 30 amino acids of TGF-fl. Antibody
localization ofTGF-/ is indicated by brown staining: Giemsa and May-Grunwald counterstains have been used. (a) Human colon
villoglandular polyp with severely dysplastic foci fixed sequentially in formalin and Bouin's solution. Detection system: avidin-
biotin-peroxidase. (107 x); inset (429 x). (b) Hepatic granuloma induced in female Lewis rats following intraperitoneal injection of
Group A streptococcal cell walls. Fixation: Bouin's solution. Detection system: peroxidase-anti-peroxidase. (429 x).
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Figure 2 Proposed role of TGF-,B in carcinogenesis. The princi-
pal source of TGF-,B is thought to be the tumour, although all of
the participating cell types, when activated, also secrete TGF-f.
TGF-,B can act on endothelial cells and fibroblasts resulting in
angiogenesis and connective tissue elaboration, respectively. It is
proposed that autocrine growth inhibitory effects of TGF-,B on
the tumour cells have been lost in the process of malignant
transformation.
in stimulation of the growth of the tumour with accom-
panying stimulation of the development of supporting
tumour stromal elements. However, autocrine effects of the
secreted growth factors on the tumour cells themselves must
also be considered. Whereas secretion by the tumour cells of
growth factors such as PDGF (Johnsson et al., 1985) or
bombesin (Cuttitta et al., 1985) has a positive autocrine
effect, in vitro experiments have shown that the growth of
many tumour cells can be inhibited by addition of TGF-f
(Roberts et al., 1985; Moses et al., 1985; Wollenberg et al.,
1987). Thus, in terms of the proposed model (Figure 2), a
contradiction arises with respect to the role of TGF-# in
carcinogenesis. The resolution is that growth of tumour cells
need not be affected directly by TGF-,B; rather growth of the
tumour can be stimulated indirectly by TGF-# via its effects
on formation of supporting tumour stroma. In fact, loss of
responsiveness to growth inhibitory factors, such as TGF-fi,
has been proposed as a contributing mechanism to the
uncontrolled growth characteristics of neoplasms (Sporn &
Roberts, 1985).
There are at least three ways by which tumour cells might
lose their responsiveness to negative growth control by
secreted TGF-fl: (1) cells could lose the ability to activate
latent TGF-fl; (2) altered signalling mechanisms could result
in inability to properly interpret the signal generated by
interaction of TGF-f with its receptor, and (3) cells could
lose their receptors for TGF-,B. Examples can now be cited
for the first two mechanisms, and it is expected that
examples of the third will also be found. A-549 human lung
carcinoma cells divide at a high rate even though they
secrete substantial amounts of latent TGF-,B. The growth of
these cells is potently inhibited by either exogenous TGF-fl,
or by their own conditioned medium, after the TGF-,B in
that medium has been activated by treatment with acid
(Wakefield et al., 1987b). Thus these cells, by their inability
to activate the latent TGF-,B they secrete, have escaped from
that mechanism of growth control. Other transformed cells,
in contrast to their non-transformed counterparts, have lost
the ability to be inhibited by activated TGF-#, suggesting
that transformation has altered a step in the TGF-,B
signalling pathway (Lechner et al., 1983; McMahon et al.,
1986; Shipley et al., 1986).
In summary, it must be kept in mind that tumour cells
secrete many growth factors, and that many of these such as
PDGF (Johnsson et al., 1985) and bombesin (Cuttitta et al.,
1985) have direct positive autocrine effects on the growth of
the tumour cells. However, in the particular case of secretion
by tumour cells of TGF-,B, which most often inhibits their
growth, we propose, as shown in Figure 2, that tumour cells
lose the ability to interact with the peptide in an autocrine
fashion, and instead, indirectly support their growth by
paracrine action of the TGF-# they secrete on the supporting
stromal elements.
We thank Dr Ursula Heine for encouragement and help in
developing immunohistochemical techniques for TGF-fi, Dr Larry
Ellingsworth for providing the antibody used for immunohisto-
chemical staining of TGF-fl, and Dr Mary Kass for providing the
human colon specimen.
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